Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

InMed Pharmaceuticals Inc

INM ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$1.33

▲ +0.19%

Market Cap $7.31M · Vol 17.48K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$7.31M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

58.68

Momentum

Beta

1.00

vs Market

52W High

$2.48

46.27% below

52W Low

$0.58

131.74% above

Volume

17.48K

Avg 18.23K

P/B

7.70

Price-to-book

ROE

N/A

Return on equity

Free Float

99.94%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, InMed Pharmaceuticals Inc (INM) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.02%

-3.44%

-14.58%

+96.53%

YTD

+25.71%

-41.30%

-90.65%

-99.83%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-11,373,140.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-122.23% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	7.70
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	5.49M

Technical Indicators

50-Day SMA	$1.41
200-Day SMA	$1.18
RSI (14)	58.68
Beta	1.00
52-Week High	$2.48
52-Week Low	$0.58

Volume Today	17.48K
Avg Daily Volume (30D)	18.23K
Relative Volume	0.96x
Volatility (10D)	16.81
Volatility (30D)	35.90
Free Float	99.94%

Analyst Consensus

N/A

Current Price $1.33

Mean Target N/A

52W Low$0.58 52W High$2.48

Current

Target

$0.58 $2.48

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SDV3N2

ISINCA4576377002

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.14% ARGX.BR argenx SE -0.37% ARGX argenx SE -0.69% 2269.HK WuXi Biologics (Cayman) Inc. +1.56% INSM Insmed Incorporated -6.56%

Company Profile

InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.